Wang, Xiangxue; Bera, Kaustav; Barrera, Cristian; Zhou, Yu; Lu, Cheng; Vaidya, Pranjal; Fu, Pingfu; Yang, Michael; Schmid, Ralph Alexander; Berezowska, Sabina; Choi, Humberto; Velcheti, Vamsidhar; Madabhushi, Anant (2021). A prognostic and predictive computational pathology image signature for added benefit of adjuvant chemotherapy in early stage non-small-cell lung cancer. EBioMedicine, 69(103481), p. 103481. Elsevier 10.1016/j.ebiom.2021.103481
|
Text
1-s2.0-S2352396421002747-main.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (1MB) | Preview |
BACKGROUND
We developed and validated a prognostic and predictive computational pathology risk score (CoRiS) using H&E stained tissue images from patients with early-stage non-small cell lung cancer (ES-NSCLC).
METHODS
1330 patients with ES-NSCLC were acquired from 3 independent sources and divided into four cohorts D1-4. D1 comprised 100 surgery treated patients and was used to identify prognostic features via an elastic-net Cox model to predict overall and disease-free survival. CoRiS was constructed using the Cox model coefficients for the top features. The prognostic performance of CoRiS was evaluated on D2 (N=331), D3 (N=657) and D4 (N=242). Patients from D2 and D3 which comprised surgery + chemotherapy were used to validate CoRiS as predictive of added benefit to adjuvant chemotherapy (ACT) by comparing survival between different CoRiS defined risk groups.
FINDINGS
CoRiS was found to be prognostic on univariable analysis, D2 (hazard ratio (HR) = 1.41, adjusted (adj.) P = .01) and D3 (HR = 1.35, adj. P < .001). Multivariable analysis showed CoRiS was independently prognostic, D2 (HR = 1.41, adj. P < .001) and D3 (HR = 1.35, adj. P < .001), after adjusting for clinico-pathologic factors. CoRiS was also able to identify high-risk patients who derived survival benefit from ACT D2 (HR = 0.42, adj. P = .006) and D3 (HR = 0.46, adj. P = .08).
INTERPRETATION
CoRiS is a tissue non-destructive, quantitative and low-cost tool that could potentially help guide management of ES-NSCLC patients.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Service Sector > Institute of Pathology > Clinical Pathology 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Forschungsbereich Mu50 > Forschungsgruppe Thoraxchirurgie 04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Thoracic Surgery |
UniBE Contributor: |
Schmid, Ralph, Berezowska, Sabina Anna |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2352-3964 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Thomas Michael Marti |
Date Deposited: |
09 Aug 2021 16:31 |
Last Modified: |
05 Dec 2022 15:52 |
Publisher DOI: |
10.1016/j.ebiom.2021.103481 |
PubMed ID: |
34265509 |
Uncontrolled Keywords: |
Computational pathology Early-stage non-small cell lung cancer Prognostic and predictive |
BORIS DOI: |
10.48350/157722 |
URI: |
https://boris.unibe.ch/id/eprint/157722 |
Actions (login required)
 |
Edit item |